Semi-synthetic alanyl dilemnin analogs

Details Semi-synthetic alanyl dilemnin analogs Semi-synthetic alanyl dilemnin analogs

1998-04-10

2000-03-07

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530317, 530323, 530330, 530331, A61K 3812, C07K 754

Patent

active

060340584

ABSTRACT:
The didemnin class of biologically active cyclodepsipeptides, isolated from the marine tunicate Trididemnun solidum, has shown considerable antitumor, antiviral, and immunosuppressive activities. Didemnin B (DB) and most other natural didemnins contain a common macrocycle and differ only in the composition of the side chain. In the present invention, structural modifications were introduced in the side chain to afford several didemnin analogues for structure-activity relationship studies. The latter have shown that the linear side chain portion of the didemnin core structure can be altered and, in some cases, provide significant gains in bioactivities. Of the compounds synthesized the new [Ala.sup.9 ] didemnin B is the most active against the L1210 (murine leukemia) cell line, at the 0.04 ng/mL level.

REFERENCES:
patent: 4493796 (1985-01-01), Rinehart, Jr.
patent: 4948791 (1990-08-01), Rinehart, Jr. et al.
patent: 5137870 (1992-08-01), Rinehart
patent: 5294603 (1994-03-01), Rinehart
patent: 5834586 (1998-11-01), Rinehart et al.
Mayer et al, Synthesis of New Didemmin B Analogs., vol. 59, No. 18, pp. 5192-5205, 1994.

Affiliated with

Also associated with

Rating

Semi-synthetic alanyl dilemnin analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Semi-synthetic alanyl dilemnin analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Semi-synthetic alanyl dilemnin analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-363114